[Market Focus] Samyang Biopharm Hits Upper Price Limit for Second Day After Spin-Off
Samyang Biopharm is hitting the upper price limit for the second consecutive day on November 25, its second day of trading after a spin-off and relisting.
As of 10:25 a.m. on this day, Samyang Biopharm is trading at 39,250 won, up 29.97% from the previous trading day. Following its spin-off from Samyang Holdings, the holding company of Samyang Group, and relisting the previous day, the stock has reached the upper limit for two consecutive days. The total number of Samyang Biopharm shares listed is 7,435,870.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Samyang Biopharm is an independent company dedicated to pharmaceutical and biotech businesses. Analysts attribute the surge in buying to heightened expectations that the spin-off and relisting will allow the company’s technological capabilities and growth potential to be more highly valued in the market. The company plans to strengthen its global competitiveness by focusing on high-performance bio products such as biodegradable surgical sutures, gene delivery systems, and anticancer drugs.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.